The earnings call showcased a successful launch of ZUNVEYL, strong revenue growth, and positive prescriber feedback, which were offset by increased operating and net losses, as well as challenges with prior authorizations. Overall, the highlights and positive indicators slightly outweigh the lowlights, suggesting a cautiously optimistic outlook.

Company Guidance

During the Alpha Cognition earnings call for the second quarter of 2025, the company highlighted several key metrics and guidance for their recent commercial activities and financial performance. The commercial launch of ZUNVEYL, a treatment for mild to moderate Alzheimer's disease, marked a significant milestone, with over 3,700 healthcare professionals (HCPs) engaged and prescriptions written in more than 300 nursing homes, 65% of which had duplicative prescriptions, indicating strong product trial. The company reported total revenue of $1.7 million, including $1.6 million from ZUNVEYL sales and $81,000 in licensing revenue from a partnership with CMS Pharmaceuticals. Operating expenses were $7.4 million, leading to a net loss of $10.5 million, primarily due to a noncash loss from changes in warrant liabilities. The company remains well-capitalized with $39.4 million in cash, and guidance for full-year 2025 operating expenses was adjusted to $34-38 million, reflecting cost optimization. The company made progress in long-term care market penetration, with 90% of ZUNVEYL orders filled despite prior authorization hurdles. Looking forward, the company aims to enhance ZUNVEYL's presence, expand payer access, and continue R&D activities, including advancing a sublingual formulation and potential new formulations, with ex-U.S. revenues anticipated by late 2026.

Successful Commercial Launch of ZUNVEYL

The second quarter of 2025 marked the successful commercial launch of ZUNVEYL for Alzheimer's disease, with prescriptions written in over 300 nursing homes and repeat prescriptions in 65% of these homes.

Revenue Growth from ZUNVEYL

Generated total revenue of $1.7 million for Q2 2025, including $1.6 million from ZUNVEYL sales.

Strong Cash Position

The company held approximately $39.4 million in unrestricted cash and cash equivalents as of June 30, 2025.

Regulatory Progress in China

ZUNVEYL's application was accepted for review by Chinese regulatory authorities, with plans to file in four additional countries by the end of 2025.

Positive Prescriber Feedback

Encouraging engagement from prescribers with 90% of ZUNVEYL orders filled, despite some payer-related hurdles.

R&D Progress with ALPHA-1062

Bomb Blast preclinical study concluded with ALPHA-1062 showing reduced neuroinflammation and potential roles in treating TBI.

Alpha Cognition Inc (ACOG) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ACOG Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Dec 02, 2025	2025 (Q3)	-0.46 / -	-0.31	―	―	―
Aug 14, 2025	2025 (Q2)	-0.46 / -0.65	-0.25	-160.00% (-0.40)	―
May 15, 2025	2025 (Q1)	- / -	-0.75	―	―
Mar 31, 2025	2024 (Q4)	-0.58 / -0.13	-0.75	82.67% (+0.62)	―
Nov 15, 2024	2024 (Q3)	-1.00 / -0.31	-0.75	58.67% (+0.44)	―	―
Aug 12, 2024	2024 (Q2)	-1.00 / -0.25	-0.75	66.67% (+0.50)	―	―
May 14, 2024	2024 (Q1)	- / -	-0.5	―	―	―
Apr 03, 2024	2023 (Q4)	- / -0.75	-0.5	-50.00% (-0.25)	―	―
Nov 28, 2023	2023 (Q3)	- / -0.75	-1	25.00% (+0.25)	―	―
Aug 22, 2023	2023 (Q2)	- / -0.75	-1.25	40.00% (+0.50)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ACOG Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 14, 2025	$9.99	$8.00	-19.92%
May 15, 2025	$6.86	$6.81	-0.73%
Mar 31, 2025	$5.53	$5.06	-8.50%
Nov 15, 2024	$5.68	$5.37	-5.46%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Alpha Cognition Inc (ACOG) report earnings?

Alpha Cognition Inc (ACOG) is schdueled to report earning on Dec 02, 2025, After Close (Confirmed).

What is Alpha Cognition Inc (ACOG) earnings time?

Alpha Cognition Inc (ACOG) earnings time is at Dec 02, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ACOG EPS forecast?

ACOG EPS forecast for the fiscal quarter 2025 (Q3) is -0.46.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing